Brief: Bridge Biotherapeutics Announces Completion Of Enrollment In The Phase 2A Clinical Study Of BBT-877 For The Treatment Of Idiopathic Pulmonary Fibrosis
29/07/2024 23:35
July 29 (Reuters) - Bridge Biotherapeutics Inc
288330.KQ :
* BRIDGE BIOTHERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT
IN THE
PHASE 2A CLINICAL STUDY OF BBT-877 FOR THE TREATMENT OF
IDIOPATHIC PULMONARY FIBROSIS
* BRIDGE BIOTHERAPEUTICS INC - TOPLINE DATA EXPECTED IN
FIRST HALF
OF 2025
Source text for Eikon: ID:nPn2qqFvda
Further company coverage: 288330.KQ
((reuters.briefs@thomsonreuters.com;))
Recent news on Parataxis Korea
See all newsBrief: Parataxis, Bridge Biotherapeutics Ink Deal to List Bitcoin Treasury Firm on Korea's KOSDAQ
Brief: Bridge Biotherapeutics Announces Completion Of Enrollment In The Phase 2A Clinical Study Of BBT-877 For The Treatment Of Idiopathic Pulmonary Fibrosis
Brief: Bridge Biotherapeutics Launches A Research Collaboration With Emory University School Of Medicine
Brief: Bridge Biotherapeutics Announces A Research Collaboration With The University Of Colorado School Of Medicine
Brief: Bridge Biotherapeutics To Conduct Capital Increase Of 2 Billion Won For Operational Funds